Quince Therapeutics’ clinical setback with its lead candidate eDSP terminated its development pipeline and R&D activity, severely constraining future growth prospects. The company has incurred accelerating net losses and operating cash flow deficits through 2025 while facing liquidity pressures reflected in a current ratio below 0.6. With no active product candidates, Quince is exploring strategic alternatives including a reverse merger to preserve shareholder value but execution uncertainty remains significant. Meanwhile, Nasdaq listing risks due to persistent low share price and dilution from equity raises and warrants add layers of investor risk.